in vitro News and Research

RSS

FDA grants 510(k) clearance for QIAGEN’s molecular detection PCR technology

QIAGEN N.V. today announced that the U.S. Food and Drug Administration (FDA) has granted two 510(k) clearances for its real-time PCR (polymerase chain reaction) instrument Rotor-Gene Q MDx and a compatible test for the detection of Influenza A/B, the artus Infl A/B RG RT-PCR Kit, for in vitro diagnostic use.

From QIAGEN Manchester Limited 17 Apr 2012

T-FET biosensor can detect biomolecules at ultra-low concentrations

A new quantum mechanical-based biosensor designed by a team at University of California, Santa Barbara offers tremendous potential for detecting biomolecules at ultra-low concentrations, from instant point-of-care disease diagnostics, to detection of trace substances for forensics and security.

17 Apr 2012

Botanical formula controls aggressive human prostate tumors in mice

A non-toxic, botanical formula controls aggressive human prostate tumors in mice, according to a peer-reviewed study in the The International Journal of Oncology. Researchers at Indiana University, Methodist Research Institute, showed the prostate formula significantly suppresses tumor growth in aggressive, hormone-refractory (androgen-independent) human prostate cancer cells.

11 Apr 2012

Eggs developed from stem cells could change reproductive technology

Scientists have developed human egg cells that have been grown entirely in the laboratory from stem cells. These could be fertilized later this year in a development that will revolutionize fertility treatment and might even lead to a reversal of the menopause in older women.

9 Apr 2012

Novel anti-leukemia compound with little toxicity successfully treats zebrafish

A novel anti-leukemia compound with little toxicity successfully treated zebrafish with T-cell acute lymphoblastic leukemia (T-ALL), suggesting its potential to become a new highly targeted therapy for humans - even those resistant to conventional therapies - according to results from a study published online today in Blood, the Journal of the American Society of Hematology (ASH).

9 Apr 2012

Internet-savvy consumers are incessant shoppers of health care providers and information

Today's Internet-savvy consumers are incessant shoppers of both health care providers and health care information, typically passing through four phases of online evaluation and connection with physicians, medical practices and other patients, according to Ron Harman King, a veteran digital marketer of specialty practices.

7 Apr 2012

Study finds alarming misconception about fertility among women

Many women do not fully appreciate the consequences of delaying motherhood, and expect that assisted reproductive technologies can reverse their aged ovarian function, Yale researchers reported in a study published in a recent issue of Fertility and Sterility.

6 Apr 2012

Novel technology to grow new primordial lung progenitors

Researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have derived a population of pure lung and thyroid progenitor cells in vitro that successfully mimic the developmental milestones of lung and thyroid tissue formation.

6 Apr 2012

Results from Abbott’s multiple interferon-free Phase 2 HCV studies to be presented at ILC 2012

Abbott will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.

5 Apr 2012

µ-PIIIA conotoxin can be effective in controlling cancer pain

Hidden in the mud, the cone snail Conus purpurascens lies in wait for its victims. It attracts its prey, fish, with its proboscis, which can move like a worm, protruding from the mud. Once a fish approaches out of curiosity, the snail will rapidly shoot a harpoon at it, which consists of an evolutionarily modified tooth. The paralyzed victim then becomes an easy meal. It takes the venomous cone snail about two weeks to digest a fish. During this time, its venomous harpoon is also replaced.

5 Apr 2012

Removing SR-BI receptor may help protect against breast cancer

Removing a lipoprotein receptor known as SR-BI may help protect against breast cancer, as suggested by new findings presented at the American Association for Cancer Research Annual Meeting 2012 by Jefferson's Kimmel Cancer Center researchers.

4 Apr 2012

Lilly announces results of three preclinical studies that focus on c-MET receptor

Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.

3 Apr 2012

Cell graphs link structure of human tissue to corresponding biological function

Computer scientists and biologists in the Data Science Research Center at Rensselaer Polytechnic Institute have developed a rare collaboration between the two very different fields to pick apart a fundamental roadblock to progress in modern medicine. Their unique partnership has uncovered a new computational model called "cell graphs" that links the structure of human tissue to its corresponding biological function.

3 Apr 2012

Novel tetracyclines with improved potency, efficacy against contemporary P. aeruginosa isolates

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results from studies that demonstrate the improved potency and pharmacokinetics of several of its newest discovery-stage tetracycline analogs.

2 Apr 2012

Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pain

Nektar Therapeutics announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate.

2 Apr 2012

Blocking PRC2 protein may help protect against AML

Scientists at Cold Spring Harbor Laboratory have identified a candidate drug target for treating acute myeloid leukemia, a white blood cell cancer that proliferates out of control in the bone marrow.

2 Apr 2012

Bruker acquires SkyScan

Bruker Corporation today announced that it has acquired all of the shares of SkyScan N.V., a scientific instruments company located near Antwerp, Belgium. Financial details were not disclosed. For the remainder for 2012, the acquisition of SkyScan is expected to add approximately $13 million to Bruker's revenue and to be accretive to EPS by about $0.01.

2 Apr 2012

New paradigm for immunotherapy against cancer

Scientists may have discovered a new paradigm for immunotherapy against cancer by priming antibodies and T cells with cancer stem cells, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.

2 Apr 2012

STAT-1 and PLSCR-1 proteins could play a crucial role in breast cancer

At the time of diagnosis, the majority of breast cancers are categorized as estrogen-receptor positive, or hormone sensitive, which means their cancerous cells may need estrogen to grow. Patients with this type of cancer often respond favorably to treatments called aromatase inhibitors, like tamoxifen, which cause cell death by preventing estrogen from reaching the cancerous cells.

2 Apr 2012

Data from Cempra's CEM-101 Phase 2 trial on N. gonorrhoeae infections to be presented at ECCMID

Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrating that CEM-101 (solithromycin) is active against antibiotic-resistant strains of N. gonorrhoeae.

31 Mar 2012